A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system

Vox Sanguinis

Volumn 91, Issue 1, 2006, Pages 56-62

  Burnouf, T ^a   Goubran, H A ^b   Radosevich, M ^a   Sayed, M A ^c   Gorgy, G ^d   El Ekiaby, M ^d  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b CAIRO UNIVERSITY   (Egypt)

^c FAYOUM UNIVERSITY   (Egypt)

^d Shabrawishi Hospital Blood Bank   (Egypt)

Author keywords

Cryoprecipitate; Factor VIII; Fibrinogen; Solvent detergent; Virus; Von Willebrand

Indexed keywords

BLOOD CLOTTING FACTOR 8; CASTOR OIL; DETERGENT; FIBRINOGEN; RISTOCETIN; RISTOCETIN COFACTOR VON WILLEBRAND FACTOR; SOLVENT; TRIBUTYL PHOSPHATE; TYLOXAPOL; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD BANK; CENTRIFUGATION; CRYOPRECIPITATE; DISINFECTION; DISPOSABLE BAG SYSTEM; DISPOSABLE EQUIPMENT; EXTRACTION; FIBRINOGEN DEFECT; HEMOPHILIA A; HUMAN; INTERNATIONAL NORMALIZED RATIO; MINIPOOL PROCESS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROCESSING; PRODUCT RECOVERY; PROTHROMBIN TIME; SUBSTITUTION THERAPY; VIRUS INACTIVATION; VON WILLEBRAND DISEASE;

BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; BLOOD PRESERVATION; CRYOPRESERVATION; DETERGENTS; DEVELOPING COUNTRIES; FACTOR VIII; FIBRINOGEN; HEMOPHILIA A; HUMANS; OCTOXYNOL; PHOSPHORIC ACID ESTERS; VIRUS DISEASES; VIRUS INACTIVATION;

EID: 33744751819     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00772.x     Document Type: Article

References (45)

1. Farrugia A: Product delivery in the developing world: options, opportunities and threats. Haemophilia 2004 10: 77 82
2. Evatt B: World Federation of Hemophilia Guide to Developing a National Patient Registry. Montréal, World Federation of Hemophilia, 2005: 1 40
3. Evatt BL Austin H Leon G Ruiz-Saez A De Bosch N: Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999 5: 295 300
4. Lloyd S: The Preparation of Single Donor Cryoprecipitate - Revised Edition. Montréal, World Federation of Hemophilia, 2004: 1 9
5. Nuchprayoon I Sahasittiwat S Kittikalayawong A Chantanakajornfung A: Lyophilized cryoprecipitate for children with hemophilia A. J Med Assoc Thai 2002 85: S293 S297
6. Mathews V Srivastava A Nair SC Chandy M: Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease. Natl Med J India 2000 13: 188 190
7. Srivastava A: Factor replacement for haemophilia - should cryoprecipitate be used? Haemophilia 1999 5: 301 305
8. Kasper CK: Products for clotting factor replacement in developing countries. Semin Thromb Hemost 2005 31: 507 512
9. Mannucci PM: Management of von Willebrand disease in developing countries. Semin Thromb Hemost 2005 31: 602 609
10. Burnouf T Radosevich M Goubran H: Local Hemostatic Blood Products: Fibrin Sealant and Platelet Gel. Monograph. Montréal, World Federation of Hemophilia, 2004: 1 14
11. Pantanowitz L Kruskall MS Uhl L: Cryoprecipitate. Patterns of use. Am J Clin Pathol 2003 119: 874 881
12. Khaja MN Madhavi C Thippavazzula R Nafeesa F Habib AM Habibullah CM Guntaka RV: High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. Infect Genet Evol 2006 in press
13. Uneke CJ Ogbu O Inyama PU Anyanwu GI Njoku MO Idoko JH: Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005 100: 13 16
14. Sallam TA Tong CY Cuevas LE Raja'a YA Othman AM Al-Kharsa KR: Prevalence of blood-borne viral hepatitis in different communities in Yemen. Epidemiol Infect 2003 131: 771 775
15. Tareen S Eslick GD Kam EP Byles JE Durrani AB Maree SM: High prevalence of hepatitis B virus (HBV) among male blood donors in a developing country: urgent need for systematic screening. Scand J Infect Dis 2002 34: 712 713
16. Songsivilai S Jinathongthai S Wongsena W Tiangpitayakorn C Dharakul T: High prevalence of hepatitis C infection among blood donors in northeastern Thailand. Am J Trop Med Hyg 1997 57: 66 69
17. Arthur RR Hassan NF Abdallah MY el-Sharkawy MS Saad MD Hackbart BG Imam IZ: Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg 1997 91: 271 274
18. Asamoah-Odei E Garcia Calleja JM Boerma JT: HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences. Lancet 2004 364: 35 40
19. Matsika-Claquin MD Massanga M Menard D Mazi-Nzapako J Tenegbia JP Mandeng MJ Willybiro-Sacko J Fontanet A Talarmin A: HIV epidemic in Central African Republic: high prevalence rates in both rural and urban areas. J Med Virol 2004 72: 358 362
20. Chuansumrit A Isarangkura P Chantanakajornfung A Kuhathong K Pintadit P Jitpraphai C Hathirat P Nuchprayoon C: The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. J Med Assoc Thai 1999 82: S69 S73
21. Horowitz B Wiebe ME Lippin A Stryker MH: Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion 1985 25: 516 522
22. Horowitz B Bonomo R Prince AM Chin SN Brotman B Shulman RW: Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992 79: 826 831
23. Burnouf T Radosevich M: Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000 14: 94 110
24. Horowitz B Minor P Morgenthaler JJ Burnouf T McIntosh R Padilla A Thorpe R van Aken WG: WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 2004 924: 1 232. [backcover]
25. Burnouf T Radosevich M El-Ekiaby M Satoh S Sato T Amin SN Savidge GF Goubran HA: Nanofiltration of single plasma donations: feasibility study. Vox Sang 2003 84: 111 119
26. Burnouf T Goubran H Radosevich M Sayed MA Gorgy G El-Ekiaby M: Mini-pool solvent/detergent treatment of plasma for transfusion using a single-use bag system. Transfusion in press
27. Clauss A: Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957 17: 237
28. Piquet Y Janvier G Selosse P Doutremepuich C Jouneau J Nicolle G Platel D Vezon G: Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 1992 63: 251 256
29. Burnouf T Burnouf-Radosevich M Huart JJ Goudemand M: A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 1991 60: 8 15
30. Prince AM Horowitz B Brotman B Huima T Richardson L van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang 1984 46: 36 43
31. Prince AM Horowitz B Dichtelmueller H Stephan W Gallo RC: Quantitative assays for evaluation of HTLV-III inactivation procedures: tri (N-butyl) phosphate: sodium cholate and beta-propiolactone. Cancer Res 1985 45: 4592s 4594s
32. Prince AM Horowitz B Brotman B: Sterilisation of hepatitis and HTLV-III viruses by exposure to tri (n-butyl) phosphate and sodium cholate. Lancet 1986 1: 706 710
33. Edwards CA Piet MP Chin S Horowitz B: Tri (n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987 52: 53 59
34. Piszkiewicz D Sun CS Tondreau SC: Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemofil M). Thromb Res 1989 55: 627 634
35. Piet MP Chin S Prince AM Brotman B Cundell AM Horowitz B: The use of tri (n-butyl) phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990 30: 591 598
36. Woods KR Orme T: New York Blood Center, assignee. Removal of lipid-soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof. USA patent 4 789 545. 31 March 1986.
37. Horowitz B Prince AM Hamman J Watklevicz C: Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinolysis 1994 5 Suppl 3 S21 S28 [discussion S29-S30]
38. Smit Sibinga CT Schulting PJ Notebomer J Das PC Marrink J vd Meer J: Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment. Blut 1988 56: 111 116
39. Allersma DP Roeffen E Van der Does JA Briet E: Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis. Pharm Weekbl Sci 1991 13: 18 23
40. Lambrecht B Mohr H Knuver-Hopf J Schmitt H: Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991 60: 207 213
41. Keeling DM Luddington R Allain JP Lawrie AS Williamson LM: Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 1997 96: 194 197
42. Hornsey VS Krailadsiri P MacDonald S Seghatchian J Williamson LM Prowse CV: Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol 2000 109: 665 670
43. Aznar JA Bonanad S Montoro JM Hurtado C Cid AR Soler MA De Miguel A: Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000 79: 156 160
44. Hornsey VS Young DA Docherty A Hughes W Prowse CV: Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Transfus Med 2004 14: 369 374
45. Farrugia A: Safety and supply of haemophilia products: worldwide perspectives. Haemophilia 2004 10: 327 333